The limited efficacy of immunotherapy single-agent in EGFR mutant NSCLC was already recognized in the advanced setting [39], probably related to the low T-cell infiltration and tumor mutational burden and the intrinsic lack of immunogenicity of the oncogene-addicted disease [40]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.